Inside OpenEvidence: The $12B Business Model

How it started (problem, solution, target audience)

Let’s be honest. Doctors are drowning. There are 1.5 million new medical papers published every single year. The total sum of medical literature literally doubles every five years. If a doctor actually tried to stay current just by reading the top ten journals and new specialty guidelines, it would eat up nine hours of their day, every day. It’s impossible.

So, founders Daniel Nadler and Zachary Ziegler looked at this mess and started OpenEvidence. The solution they built is a medical search engine and chatbot trained exclusively on medical papers and textbooks. It lets doctors ask incredibly complex clinical questions and get fully cited, evidence-based answers in five to ten seconds. The core target audience is verified doctors, though the vision stretches to nurses, pharmacists, and medical students.

Competitive advantage

You want a moat? Here is the kicker. OpenEvidence didn’t just build a smart model. They locked down the actual gold-standard data. They secured exclusive content partnerships with the American Medical Association, The New England Journal of Medicine, and the JAMA Network.

Speed and scale matter too. They were early movers, and now they have tens of millions of clinical consultations feeding their systems. But the real wedge is pricing. Competitors like UpToDate charge hospitals $500 a seat. OpenEvidence gives its core product to doctors completely for free.

Marketing Technique of OpenEvidence

Selling into healthcare usually means brutal 18-month enterprise sales cycles. It’s a grind. It’s slow. But it works if you bypass the hospital entirely.

• Word-of-mouth: They gave the tool directly to doctors for free. Organic growth through physician word-of-mouth exploded.
• Strategic Integrations: You have to be where the actual work happens. They are embedding directly into Epic’s electronic health records, like their recent setup at Sutter Health.
• Advertising Infrastructure: To make the free model work at scale, they acquired Amaro, a Google Ventures-backed startup, to build an automated, modern advertising engine.

Business Quiz

Welcome to your Check your business knowledge

1. 

What significant metric regarding doctor adoption in the U.S. did OpenEvidence report as of late 2025?

Used daily by over 40% of U.S. physicians

A total of 100,000 verified users globally

Mandated by the FDA for all oncology clinics

Exclusively used in top-tier research universities

None

2. 

Why did OpenEvidence acquire the startup Amaro in September 2025?

To gain access to specialized veterinary data

To build a user-first advertising infrastructure

To expand its clinical search into the legal domain

To obtain patents for drug discovery

None

3. 

What is the primary purpose of the 'DeepConsult' AI agent released by OpenEvidence in mid-2025?

Matching patients directly with pharmaceutical sales reps

Automating Ph.D.-level medical research reports

Transcribing patient conversations into notes

Managing hospital staff schedules

None

4. 

What is a key differentiator between OpenEvidence and general-purpose LLMs like ChatGPT regarding medical trust?

Automated diagnosis of patient symptoms

A built-in video consultation feature

Integration with public social media forums

Exclusive content licensing from peer-reviewed journals

None

5. 

How does OpenEvidence primarily generate revenue while keeping its platform free for verified physicians?

Licensing medical data to LLM developers

Per-patient consultation fees

Pharmaceutical advertising

Hospital enterprise subscriptions

None

6. 

Which company, founded by Daniel Nadler before starting OpenEvidence, was sold to S&P Global for $700 million?

UpToDate

Amaro

Doximity

Kensho Technologies

None

1 out of 6

Time’s up

How OpenEvidence makes money

The reality is, if you give a product away to users, someone else has to pay for it. Right now, pharmaceutical and medical device companies are footing the bill. OpenEvidence runs an ad-supported model. Because they offer an incredibly targeted audience of high-intent U.S. prescribers, they charge massive premiums-we’re talking $70 to $150 CPMs. Compare that to the $5 to $15 you’d get on Facebook.

And the numbers back it up. They hit $100 million in annual revenue by January 2026. Down the line, they are setting up enterprise per-seat pricing for health systems and licensing out data insights.

Market share of OpenEvidence

The penetration they’ve achieved is frankly absurd for a clinical tool.

Business Model canvas of OpenEvidence

• Value Proposition: Evidence-based, cited clinical answers delivered in 5-10 seconds.
• Customer Segments: Doctors who use the tool, and pharma companies who pay for the eyeballs.
• Channels: Direct-to-physician web and mobile apps, plus deep EHR integrations.
• Customer Relationships: Free, high-value utility built directly into the daily workflow.
• Revenue Streams: High-CPM pharma ads right now, evolving toward enterprise SaaS and data subscriptions.
• Key Resources: Massive compute power and exclusive medical publisher databases.
• Key Activities: Training specialized models, rapid evidence retrieval, and matching patients to clinical trials.
• Key Partnerships: The heavyweights. NEJM, JAMA, Mayo Clinic, and Veeva.
• Cost Structure: Heavy compute costs for training models, plus talent and content licensing.

Conclusion: Is it a viable business

So, is this a real business? Absolutely. They just raised a $250 million series D that pushed their valuation to $12 billion. They found a brilliant wedge: bypass hospital procurement, give doctors a killer free tool, and charge pharma a premium.

But let’s be honest, it’s not all smooth sailing. At $12 billion, they are trading at a 120x revenue multiple. You have to keep growing at a breakneck pace to justify that. They are also staring down entrenched giants like Epic and massive tech players like OpenAI and Anthropic who want a piece of the healthcare pie. To survive the long game, they need to successfully transition from a free physician app into the embedded infrastructure of clinical care.

Resources used –

• Crunchbase News
• Nelson Advisors
• Sacra
• PR Newswire